

Impact of Pharmacovigilance Systems

 4^{th} industry stakeholder platform - operation of EU pharmacovigilance legislation – 12 June 2015

Almath Spooner, PRAC Peter Arlett, EMA Xavier Kurz, EMA Jacoline Bouvy, EMA Marie-Helene Pinheiro, EMA






Disclaimer

The strategy on impact evaluation of pharmacovigilance Systems is under development and may change following consultation of EMA committees



Approach

- Health-focused
- Science-based
- Leverage ongoing work
 - Academia
 - Industry
- Prioritisation key tools and methods



Impact Evaluation

- Key element of the approach is the (bi-)annual measurement of:
 - Pharmacovigilance activities
 - System outputs
 - Stakeholder engagement
 - Patients, Healthcare professionals, Industry, NCAs
 - Effectiveness regulatory actions
 - Resources





Data to be collected for evaluation:

PhV system outcome measure	Components
Regulatory actions	 SmPC changes Educational material to advice to modify/change behaviour of patients/HCPs DHPCs Restrictions of indications Withdrawals Suspensions/revocations
Effectiveness of regulatory actions	 Changes in the behaviour of patients resulting from regulatory communications regarding marketed products Changes in the behaviour of HCPs resulting from regulatory communications regarding marketed products
Stakeholder engagement	 Engagement of patients and HCPs in the pharmacovigilance system and in regulatory communications.
Resources	Possible survey

Moving forward

- Report on PhV tasks: this year
- 2018: report on impact of pharmacovigilance (outcomes)
- Development of strategy for impact evaluation with PRAC
- Collaborate with industry on development of tools
- Set-up of virtual interface with industry Stakeholders
 - Explore what existing data sources and activities might provide required data
 - Provide input in development of possible survey

Virtual interphase group

- Two members from interested EU industry stakeholders organisation
- Intends to provide input on:
 - Existing initiatives and activities that could be utilised for impact evaluation
 - Development of possible survey
- Nominations to <u>Patricia.kaniki@ema.europa.eu</u>, by end of June 2015